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Introduction 
The success of heart-lung and lung transplantation 
has given hope to patients with various end stage lung 
diseases (l-5). Since the first successful heart-lung 
transplantation was performed at Stanford in 198 1 (1), 
more than 300 heart-lung, single and double-lung 
transplants are performed each year in more than 250 
centres around the world (3). With the advancement in 
technical skills, improved management of severe infec- 
tions and early rejections, more and more transplants 
are performed successfully and early results are con- 
stantly improving ($6). Recent reports suggest that 
the 1 yr survival in some centres following single lung 
and heart-lung transplantation may reach 90% and 
75% respectively(5-7).Themajorobstacleforcontinu- 
ous survival and a morbidity-free life is the develop- 
ment of bronchiolitis obliterans, an unexplained, often 
non-reversible condition unresponsive to therapy and 
in most cases fatal (9). Since its first description by 
Burke in 1984 (lo), it has been a continuous challenge 
for any lung transplant team world-wide. 
Definition 
Bronchiolitis obliterans (BO) is an inflammatory 
process involving small airways, leading to plugging 
and destruction of bronchioles while causing a rapidly 
progressive often non-reversible obstructive airway 
disease. 
Incidence 
The incidence of BO after lung transplantation 
varies from centre to centre and from one report to 
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another. It is quite difficult to estimate the true inci- 
dence of BO as there is large variability in early death 
rates, mean follow-up periods and differences in reports 
(% of total cases vs. % of long term survivors) and 
even in terminology (Chronic rejection vs. BO). It is 
quite natural that newer programs with only a short 
follow-up period report low incidence of BO while 
those with longer follow-up have higher rates of BO. 
Table 1 gives a summary of recent reports. Overall 
incidence can be estimated to be between 30-50% of 
those who survive more than 6 months following the 
procedure (5-15). 
Early reports have suggested that single lung trans- 
plantation has less frequent BO than heart-lung recipi- 
ents (16). However, as follow-up has become longer 
and experience enlarged, it seems that the differences 
are not that significant (7). Similarly, some centres 
have suggested that patients with cystic fibrosis have 
lower incidence of BO following transplantation as 
compared to patients with pulmonary hypertension 
(17) but again, looking at the large series of CF 
patients from Harefield (12) with a longer follow-up 
there is an incidence of 17,23 and 48% at 1,2, and 3 yr 
following transplantation respectively. In the pediatric 
population the incidence of BO can be as high as 80% 
of patients (18). 
Timing of BO 
Reports from early autopsies have shown that BO 
can occur as early as 2 months post transplantation 
(10). Most cases, however, appear between 6-18 
months after the transplant. Figure 1 shows timing of 
occurrence of BO at Stanford which peaks between 7 
and 12 months after the transplant. Later occurrence is 
not infrequent and BO has occurred in a patient 7 yr 
post heart-lung transplantation without any prior evi- 
dence of pulmonary function abnormality. (Theodore, 
personal communication.) 
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Table I Incidence of BO after hearttlung transplantation 
No. of Incidence 
Centre Transplants Years Type (%I Ref No. 
Stanford 65 81-89 H/L 40 6 
Minnesota 44 88891 H/L 22 11 
DLjSL 19 
Harfield 79 84-89 H/L 48 12 
PI 
Papworth 75 8690 H/L 24 13,14 
Pittsburgh 60 82-91 H/L 2@49 15 
Toronto 90 83-91 DL/SL 1420 8 
1 2 3 4-6 7-1213-24 >24 
Months post transplant 
Fig. 1 Timing of obliterative bronchiolitis after transplan- 
tation - Stanford experience. 
Clinical Manifestations 
The clinical onset of BO is often insidious with mild 
symptomatology which may include mild cough, some- 
times associated with minimal sputum production, and 
exertional dyspoena. In some cases a ‘viral syndrome’ 
of upper respiratory tract infection may precede the 
development of the full blown picture. Later on, a 
rapidly progressive obstructive airways disease occurs 
with the development of dyspnoea, hypoxemia and 
recurrent bronchitis often with purulent sputum pro- 
duction. Unlike typical obstructive airway disease 
such as emphysema or chronic bronchitis, the clinical 
course of BO is rapid with deterioration of the lung 
function from practically normal to an end stage 
within several months (9,13). 
Pulmonary Function 
Serial pulmonary function measurements which are 
performed routinely in lung transplant patients reveal 
a dramatic decline in flow rates, initially involving the 
small airways with decline of the FEF,,-,, or FEF,, and 
later on, a constant decline in FEV, to levels below 
Months post transplant 
Fig. 2 Pulmonary function of a 17-year-old patient with 
Eisenmenger’s syndrome having hearttlung transplantation. 
Note the rapid decline in expiratory flow rates (FEF zs75, 0) 
and increase in A-a gradient (0). Patient had retransplan- 
tation at 14 months after initial transplant. 
I I I 
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Volume (1) 
Fig. 3 Shape of flow-volume loop in same patient as Fig. 2. 
30% predicted. Figures 2 and 3 show a typical case of 
BO occurring in a 17-year-old heart-lung recipient 8 
months following a successful transplant. Note the 
rapid downhill course following an ‘upper respiratory 
tract infection’ and ending with retransplantation. 
Hypoxemia commonly follows the flow rate decline 
with hypocarbia and widened A-a gradient. In contrast 
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to classic forms of COPD, lung volumes are not 
increased and a reduction in lung volumes is common, 
thus creating a mixed obstructive and restrictive pat- 
tern. Diffusion capacity is usually decreased even after 
correction for volume, probably due to the interstitial 
fibrosis associated with the airways disease. 
In the single lung transplant, moderate restriction 
could be seen prior to the development of BO due to 
the effect of the remaining lung. However, when BO 
develops the obstructive pattern is prominent 
Imaging Features 
Chest films are often normal in most cases with BO 
(20). When disease progresses some parenchymal 
changes can be observed which include either nodular, 
linear or diffuse alveolar opacities (20,21). These 
changes are not specific for BO and are indistinguish- 
able from other post-transplant complications that 
should be excluded. High resolution CT can show 
bronchial dilatation mainly in the lower lobes (22). 
Ventilation-perfusion abnormalities are common (23) 
but are non-specific. 
Diagnosis 
The diagnosis of BO can be made by either the clini- 
cal or pathological picture. Clinically, the develop- 
ment of rapidly progressive obstructive airway disease 
following transplantation which is not due to infection 
or acute rejection and does not resolve within 6-8 
weeks is highly suggestive of BO. As acute rejection 
may also manifest with small airway obstruction a trial 
of pulse steroids is always indicated. However, if no 
response is observed and transbronchial lung biopsy 
does not show rejection (24) the diagnosis of BO is 
highly probable . Pathologically, BO can be diagnosed 
by transbronchial biopsy. However, as the disease is 
patchy in nature, the yield of TBB is quite low and 
diagnosis is frequently missed (25). Nevertheless, 
bronchoscopy with bronchoalveolar lavage and trans- 
bronchial biopsy should always be performed to rule 
out rejection and acute infection as a cause of pul- 
monary function deterioration. If TBB is negative, 
however, BO should be suspected if the physiological 
picture is compatible. Open lung biopsy can easily 
make the diagnosis but this may jeopardize the option 
of retransplantation when lung function further de- 
creases. Therefore, the diagnosis should be based 
mainly on the physiologic picture. 
Pathology (Plate 1) 
The initial pathological changes include inflam- 
mation of the terminal and respiratory bronchioles. 
This is manifested by lymphocytic and plasma cell 
infiltration around the bronchioles. Further early 
changes include denuding and ulceration of the 
ciliated respiratory epithelium with sloughing of 
necrotic debris into the lumen. Later on, fibroblasts 
grow into the area, creating intraluminal plugs of 
myxoid tissue with concentric sheets of matured 
collagen, enveloping the central necrotic material, thus 
creating onion shaped plugs. This process creates a 
rigid bronchiole which may be filled with debris 
(19,26). 
Subsequently, proximal bronchiectasis develops 
and is often filled with bacteria and necrotic debris due 
to recurrent infection. 
Early changes could be misinterpreted as BO and 
include bronchiolitis obliterans organizing pneumonia 
(BOOP) associated with acute infection or rejection. 
Unlike BO, these pathological changes usually resolve 
without permanent damage. 
Etiology 
Although much has been written on the possible 
etiological factors and pathogenesis of BO, to date no 
definite answers exist as to the basic mechanism by 
which BO develops nor the means to treat or prevent it. 
The Chronic Rejection Theory 
Acute rejection of lung allograft is a common 
complication in the early postoperative period. Both 
the Pittsburgh group (27) and Papworth group (28) 
have shown good correlation between multiple early 
rejection episodes and late occurrence of BO. However, 
BO has been seen in patients without evidence of early 
rejection. 
The Pittsburgh group have studied extensively the 
properties of bronchoalveolar lavage lymphocytes 
alloreactivity on the occurrence of BO. They have 
found good correlation between donor-specific pro- 
liferative response of BAL lymphocytes to acute and 
chronic rejection (29,30). However, a positive reaction 
was seen in some patients without rejection as well. 
Positive correlation between a greater HLA mis- 
match and BO was noted in an early report from 
Stanford (31) but was not repeated by other centres. 
HLA-class II antigen expression is increased in epi- 
thelium as well as endothelium of patients with BO, 
suggesting again increased antigenic stimuli as a 
cause of rejection. This phenomenon, however, is not 
specific (32,33). 
Further studies show evidence of accumulation of 
CD8 lymphocytes aroung bronchioles affected by BO, 
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Plate I Lung biopsy of a patient with BO. Note the onion shaped fibrotic plug in a terminal bronchiole (a) and lymphocytic 
infiltration next to the fibrotic bronchiole(b). 
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again suggesting an immunologic mechanism, i.e. 
rejection (34). 
Graft-versus-host disease following bone marrow 
allograft transplantation is considered a classic 
immunologic rejection. One of the important manifes- 
tations of this syndrome is the development of obstruc- 
tive airway disease which is identical to BO following 
lung transplantation (35). This further suggests a rejec- 
tion mechanism although the exact pathogenesis in 
both clinical settings is still unknown. 
Against the chronic rejection theory are several 
facts: Despite early reports, patients with BO do not 
respond to augmented immunosuppression and most 
of them succumb to fatal end-stage lung disease or 
require retransplantation. Moreover, in many patients 
the course is not chronic at all and a rapid course 
occurs after an 8-12 month period of normal lung 
function. Furthermore, no correlation was found 
between level of immunosuppression and BO. In 
addition, cases with no evidence of early rejection may 
develop BO eventually. 
The Infection Theory 
Infections are common following lung transplan- 
tation and therefore it is not surprising that some 
investigators believe they are the cause of airway 
damage and BO. It is well known that adenovirus can 
cause bronchiohtis in children (36) and BO in the non- 
transplant population (37). Viral infections have been 
associated with rejection of transplanted kidneys and 
cytomegalovirus (CMV) infection is commonly associ- 
ated with lung as well as heart and renal acute rejec- 
tion. Infection with Pneumocystis carinii as well as 
bacterial infection have been associated with increased 
rate of BO (38). Recently, evidence has been accumu- 
lating in favour of the role of CMV infection in the 
development of BO. The Pittsburgh group have shown 
that CMV positive recipients had a much higher inci- 
dence of BO than CMV negative patients although this 
has not reached statistical significance (l&39,40). 
Patients with proven CMV pneumonitis had signifi- 
cantly more BO and worse prognosis in general. It 
was assumed that CMV antigen can induce prolifer- 
ation of lymphocytes which accelerate rejection (41). 
Correlation of OB and CMV infection was not clearly 
supported by data by Scott et al. from Papworth (27). 
Moreover, prophylactic therapy with Gancyclovir has 
not yet been shown to reduce occurrence of BO. It is 
important to remember that 70-80% of all donors 
and recipients are CMV positive and it is extremely 
difficult to isolate this factor as the sole cause of BO. 
At Stanford, BO was noted in one case following a 
documented adenovirus infection (42) and the rapid 
course of BO seen in some cases resembles an infection 
episode. 
Many researchers favour a combined theory: an 
infection (viral/CMV) that up-regulates expression of 
MHC-II antigens at the epithehum or endothelium. 
This is followed by T-cell activation and an inflamma- 
tory process which is targeted on the bronchioles and 
subsequently results in fibrosis (40,41,43). 
Other Theories 
Some reports associate gastric content aspiration as 
a cause of BO. This is supported by evidence of 
increased esophageal reflux and slow gastric emptying 
secondary to vagal nerve injury or cyclosporin therapy 
W). 
Other theories include direct cyclosporin toxicity on 
the lungs which seems less likely as BO is not associated 
with other solid organ transplants. 
The reduction of mucocilliary clearance which is 
a common sequel of lung transplantation can also 
increase risk of infection/inflammation at the 
bronchiolar level and contribute to late fibrosis. 
Another possibility is ischemic damage to the trans- 
planted lung occurring either immediately at the time 
of transplantation or later as a result of lack of 
bronchial circulation (5). 
Therapy and Management 
Once the diagnosis of BO is established, a trial of 
enhanced immunosuppression is usually indicated. 
However, despite early reports on arrest of the lung 
function deterioration with augmentation of therapy 
(increased steroid dose) (42,45), the accumulating 
experience suggests that BO cannot be reversed in 
most cases. The goal of therapy should therefore be 
reduction of further airways damage by control of 
recurrent infections. The bronchiectasis which com- 
monly occurs in these patients is frequently infected 
with Gram-negative bacteria (Pseudomonas sp) and 
requires frequent antibiotic therapy (46). 
Retransplantation 
When lung function further deteriorates and reaches 
end-stage, the possibility of retransplantation is 
always considered and poses a serious dilemma. On 
one hand, the responsibility towards the transplanted 
patient in whom the initial attempt failed, and the 
great effort invested, favours retransplantation. On the 
other hand, results of retransplantation in most centres 
are poor, probably due to the condition of the candi- 
date, the redo procedure, and the recurrent infections. 
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Moreover, in view of organ shortage, a new candidate 
has a much higher chance to benefit from a transplant 
than a redo procedure. Another problem yet to be 
solved is what kind of a transplant should be done-a 
single lung or a double/heart-lung? The fibrosis favours 
single lung, but many patients are chronically infected 
in both lungs and a double heart-lung transplantation 
should therefore be preferred. 
Prognosis and Outcome 
Theodore et al. (47) reported a group of 12 patients 
with post-transplant BO with poor lung function who 
were able to survive up to 36 months after diagnosis of 
BO. Initially, these patients were not hypoxemic and 
could maintain a fair quality of life. In most BO cases, 
however, lung function deteriorates within several 
months and death or retransplantation follows. 
Future aspects of research to prevent or decrease the 
incidence of this devastating complication include a 
search for better immunosuppressive agents, better 
control or prevention of viral/CMV infections and 
perhaps better ways to improve arterial circulation to 
the lung. 
In conclusion, BO is still the most frustrating com- 
plication of lung transplantation arising in about 40% 
of all recipients. Despite extensive research, pathogen- 
esis of this syndrome is still obscure and once disease 
has occurred the prognosis is extremely poor. After 
recent successes in technical and early post-operative 
management of patients with lung transplantation, 
BO remains the major threat to long-term survival and 
is still awaiting a major breakthrough. 
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